RWE4Decisions Symposium: Developing Real-World Evidence to Deliver Innovation in HTA

On 14 November, from 09:00 to 13:00 CET, RWE4Decisions will host its annual hybrid Symposium in Brussels: “Developing Real-World Evidence to Deliver Innovation in HTA“.

This year we will explore how Real-World Evidence can drive innovation in Health Technology Assessment (HTA), focusing on the implications of the implementation of the European Health Data Space and HTA Regulation on HTA/Payer decisions across the European Union.

During the Symposium, we will also launch our updated Stakeholder Actions to Generate Better Outcomes for HTA/Payers, reflecting the latest policy and landscape changes since the 2020 version.

Stay tuned for more announcements.

Confirmed Speakers

MEP Tomislav Sokol

Member of the European Parliament’s Committee on the Environment, Public Health and Food Safety and Sub-committee on Public Health

Enrique Terol Garcia

Coordinating Advisor on Health, Permanent Representation of Spain to the European Union

Patrice Verpillat

Head of Real-World Evidence, European Medicines Agency

Dr Johan De Cock

Senior Adviser and former CEO, Belgian Institute for Health and Disability Insurance (INAMI-RIZIV)

Piia Rannanheimo

Chief Specialist, Finnish Medicines Agency (Fimea)

Dr Carlos Martín Saborido

Advisory Member, Directorate General for Common Portfolio of SNS and Pharmacy Services, Spanish Ministry of Health

Ashley Jaksa

Vice President for Scientific Strategy and Partnerships, Aetion

Anne-Pierre Pickaert

Patient representative

Dr Alexander Natz

Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Andre Vidal Pinheiro

Vice President and Head of Patient Value & Access – Europe & Canada, Takeda

François Meyer

RWE4Decisions Steering Group member & Special Adviser at FIPRA International

Karen Facey (pre-recorded intervention)

RWE4Decisions Steering Group member & Special Adviser at FIPRA International